U.S. Patent Nos.
7,485,704 (Reducing Protein A Leaching During Protein A Affinity Chromatography)
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)
8,460,895 (Method for Producing Recombinant Proteins with a Constant Content of pCO2 in the Medium)
8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media)
8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides)
9,714,293 (Production of Proteins in Glutamine-free Cell Culture Media)
10,017,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production)
10,336,983 (Method for Increasing the Specific Production Rate of Eukaryotic Cells)
10,450,379 (Method for Treating Joint Damage)
10,654,940 (Method for Treating Joint Damage)
10,662,237 (Method to Improve Virus Filtration Capacity)
10,676,710 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production)
10,759,866 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides)
10,829,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production)
10,982,003 (Production of Proteins in Glutamine-Free Cell Culture Media)
Plaintiffs
Genentech, Inc.; Biogen, Inc.; Hoffmann-La Roche Inc.
Defendants
Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, SA; Fresenius Kabi Deutschland GmbH; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi USA, LLC
Status
Settled
BPCIA
Y
FDA-Approved Indications
Approved Foreign Follow-On Biologics / Biosimilars
U.S. Patent Litigations
